Skip to content

Upstream Bio, Inc. UPB Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$2.67B+126%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$642.9M+8.7%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$22.19M-22.7%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$15.55M-8.0%
Savara logo
SavaraSVRA
-$38.99M-37.1%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s operating income?
Upstream Bio, Inc. (UPB) reported operating income of -$43.62M in Q1 2026.
How has Upstream Bio, Inc.'s operating income changed year-over-year?
Upstream Bio, Inc.'s operating income decreased by 36.2% year-over-year, from -$32.01M to -$43.62M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.